Form 4 for EDSA Edesa Biotech, Inc.
Accepted 2023-08-04 00:00:00 ET · period of report 2023-08-04 · accession 0001654954-23-010168 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-08-04 | 2023-08-04 | EDSA | Lemieux Stephen | CFO | A - Grant | — | +17.4K | 17.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-08-04 | A | A | 17,400 | — | 17,400 | D | — | — | (F1) Reflects a grant of restricted share units ("RSUs"), which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of certain compensation fees earned by Reporting Person. The number of RSUs was determined by dividing such fees by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through July 31, 2023. |